Emma Claremont
Member
- Messages
- 6
- Location
- UK
alternatives to offer our patients with type 2 diabeteThe focus of this series of investigations has been on
insulin glargine. It has not proved possible to place
insulin detemir under similar scrutiny, but it would be
prudent for this insulin analogue to be investigated in
more detail. On current evidence, the short-acting
analogues do not appear to present a potential problem.
With respect to insulin glargine, it is in no one’s interest
to mount a witch-hunt against this popular and widely
used insulin—many will reflect upon the fate of
rosiglitazone—but it is in everyone’s interest for the
truth to be known. The evidence presented in this set of
papers is sufficient to establish that there is a case to
answer, but is entirely insufficient to bring in a verdict.
Certain reassurances do, however, seem justified. There
is no evidence that insulin, however formulated, causes
cancer. There is no evidence of an overall increase in the
rate of cancer development in patients on insulin
glargine, and some suggestion that the risk may actually
be reduced. There is no evidence of harm in type 1
diabetes, or in premenopausal breast cancer. On the other
hand, it has to be said that insulin glargine has not been
shown to be more effective than human insulin in
achieving glycaemic control in type 2 diabetes; its main
benefit (if any) is in relation to symptomatic episodes of
nocturnal hypoglycaemia [49–52]. We have safe and effective
DiaBetty said:Yes it is! It was very good of you to put that link in with that info in it.You should have posted that on here yourself! We don't need scare stories,diabetes is scary enough.
cugila said:Just so people don't start to panic over this.
janabelle said:Thanks Emma for posting this subject.
I hate Lantus with a passion for the problems it caused me, and how ill it made me for the 4 1/2 years I was unfortunate to be on it.
I'm not sorry to hear negative news about Lantus, and it does not surprise me-the sooner patients get off this muck the better, in my opinion. These studies show that there are serious concerns about the safety of Lantus.
I know how ill it made me, and do worry about how it may have harmed me long term, not just the uncontrolled blood sugars; but glad I'm no longer a human ginuea pig :evil:
Jus
cugila said:Mmmmmh......
Personal opinions aside.
The EMEA are advising that patients being treated with insulin glargine should continue their treatment as normal. The advice also states that there is no immediate need to change treatment.
While this research is awaited, EASD advises that patients do not stop taking Lantus insulin on the basis of the findings reported here. However, since Lantus does not offer better overall glucose control than human insulin in type 2 diabetes, patients can consider alternatives. In an advice leaflet published with the studies, Profs Gale and Smith say: "People with diabetes do however have the option of using long acting human insulin or a mixture of long- and short-acting human insulin twice a day instead of the once-daily analogue. You may wish to consider this option if you already have a cancer, or, for women, if there is a family history of breast cancer. You should not make any change in your insulin treatment without consulting your own doctor, and you should on no account stop taking your insulin".
“People with diabetes who are using glargine insulin should continue to take their medication as prescribed. You will become very ill if you stop taking your insulin. If you are concerned about these findings then you should speak to your healthcare team about your anxieties before discontinuing any treatment.”
My aim if you read my previous post is to get ALL the facts out.
You seem to have a great deal of prepared information to hand. Perhaps I should think you also have an ulterior motive ?
Oh, by the way to consult you GP is a stock phrase to cover all eventualities. A sensible piece of advice in my view.
Thank you for your kind words. I do plan to have a great weekend. I hope you do too.
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?